Radiosensitization of C3H mouse mammary tumours by a 2-nitroimidazole drug.
Local tumour control has been determined at 150 days after single doses of 240 kV x-rays given with or without 1 mg/g body weight of the hypoxic cell radiosensitizer Ro-07-0582. The dose required to control 50% of the tumours (TCD50) was reduced from 4380 to 2410 rad, yielding an enhancement ratio of 1·82 ± 0·07 s.e.mean. This compares favourably with the corresponding single dose gain factor for fast neutrons, which was about 1·7.
D000433:1-Propanol / Q000494:pharmacology; D000818:Animals; D005260:Female; D000860:Hypoxia; D008325:Mammary Neoplasms, Experimental / Q000532:radiotherapy; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009593:Nitroimidazoles / Q000494:pharmacology*; D010101:Oxygen Consumption; D011315:Preventive Medicine; D020005:Propanols; D011838:Radiation-Sensitizing Agents; D011879:Radiotherapy Dosage; D014184:Transplantation, Homologous
D009593:Nitroimidazoles; D020005:Propanols; D011838:Radiation-Sensitizing Agents; D000433:1-Propanol